MedTrace Logo

Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide

NCT01274039 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2013-04-15

No results posted yet for this study

Summary

Local therapy for glaucoma is known to induce a conjunctival inflammation. Because of this, trabeculectomy is more likely to fail. The investigators exchange the local therapy by systemic therapy using acetazolamide and measure the eye pressure using local therapy and systemic therapy using acetazolamide. The investigators suspect an elevated eye pressure using acetazolamide compared to local therapy. In summary acetazolamide could be a better choice in reference to conjunctival inflammation, but a worse choice in reference to controlling eye pressure.

Conditions

  • Control of Elevated Eye Pressure by Local and Systemic Therapy

Interventions

DRUG

Acetazolamide for glaucoma patients to lower eye pressure

Acetazolamide tablets 3 times daily for 3 to 4 weeks

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-02-28
Completion
2012-02-29

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01274039 on ClinicalTrials.gov